Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SinoMab BioScienceHKSE:03681 -3.57%29 FCF Yield % is -6.43 as of Sep. 10, 2026. GuruFocus rates HKSE:03681 with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,406 Biotechnology companies, SinoMab BioScience ranks better than 58.82% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
SinoMab BioScience FCF Yield % Related Terms
SinoMab BioScience FCF Yield % Historical Data
* Premium members only.
The historical data trend for SinoMab BioScience's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:03681 vs VRTX, REGN, MRNA: FCF Yield % Comparison
For the Biotechnology subindustry, SinoMab BioScience's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SinoMab BioScience FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SinoMab BioScience's FCF Yield % distribution charts can be found below:
* The bar in red indicates where SinoMab BioScience's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SinoMab BioScience (HKSE:03681) has a FCF Yield % of -6.43 as of Sep. 10, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on SinoMab BioScience and its competitors. According to the industry distribution chart, SinoMab BioScience ranks #579 out of 1406 companies in the Biotechnology industry, placing it in the top 41.2%.
Is SinoMab BioScience's FCF Yield % too high?
SinoMab BioScience's current FCF Yield % is -6.43. Based on the distribution chart, SinoMab BioScience ranks #579 out of 1406 companies in the Biotechnology industry, which is above the industry midpoint. Overall, SinoMab BioScience has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does SinoMab BioScience's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SinoMab BioScience ranks #579 out of 1406 companies for FCF Yield %. This puts SinoMab BioScience in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on SinoMab BioScience and its competitors. SinoMab BioScience's current FCF Yield % is -6.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SinoMab BioScience stock overvalued right now?
SinoMab BioScience (HKSE:03681) has a current FCF Yield % of -6.43. The current FCF Yield % is -6.43. SinoMab BioScience's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For SinoMab BioScience (HKSE:03681), the current FCF Yield % is -6.43 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SinoMab BioScience Ltd is a biopharmaceutical company focused on the research, development, manufacturing, and commercialisation of therapeutics for the treatment of immunological diseases, mainly monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. In addition, the company possesses other potential first-in-class drug candidates (like SM17, SN1011, SM06, SM09, etc.) some of which are already in the clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases.
29GF Score
Get the complete analysis for HKSE:03681
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03681 has been successfully added to your 
